|
| Press Releases |
|
 |
|
| Tuesday, December 26, 2017 |
|
|
Nanobiotix: 2017 review and 2018 expected milestones |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today provides a recap of its activities and achievements in 2017 and an overview of its anticipated 2018 milestones. more info >> |
|
|
FDA approves Nanobiotix's first Immuno-Oncology trial |
| A Phase I/II Study of NBTXR3 Activated by Radiation Therapy (SABR) for Patients with Non-Small Cell Lung Cancer or Head and Neck Squamous Cell Carcinoma Cancer Treated with an Anti-PD1 Antibody (Nivolumab or Pembrolizumab) more info >> |
|
| Monday, November 13, 2017 |
|
|
Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3's significant potential role in Immuno-Oncology at SITC Annual Meeting |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, recently presented positive clinical and preclinical data from the ongoing immuno-oncology programs. These data were presented at the 32nd Annual Meeting of the Society for Immunotherapy of Cancer (SITC), held from November 8 to 12, 2017 in National Harbor, Maryland, USA. more info >> |
|
| Friday, November 10, 2017 |
|
|
Nanobiotix provides update on the global development of its lead product NBTXR3 |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today provides an update on the global development of its lead product, NBTXR3. more info >> |
|
| Monday, October 23, 2017 |
|
|
Nanobiotix Completes Patient Inclusion for Phase II/III Trial of NBTXR3 in Soft Tissue Sarcoma |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that it has completed patient inclusion for the Phase II/III trial (Act.In.Sarc) of its lead product candidate, NBTXR3, in soft tissue sarcoma. The last patients are expected to start their treatment in two to three weeks. more info >> |
|
| Friday, September 29, 2017 |
|
|
Nanobiotix plans to conduct its first clinical trial with NBTXR3 in combination with immune checkpoint inhibitors in the U.S. |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, announced today its intention to start a new trial in the company's immuno-oncology (IO) program. The trial is aimed at expanding the potential of NBTXR3 to recurrent and metastatic disease. more info >> |
|
| Friday, September 1, 2017 |
|
|
Nanobiotix half year results for the six months ended 30 June 2017 |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces its half year results for the six months ended 30 June 2017. more info >> |
|
| Friday, June 16, 2017 |
|
|
NANOBIOTIX: New Translational Data Presented at ASTRO, NCI and SITC's Immunotherapy Workshop |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today presented new translational data at the "Immunotherapy workshop - Incorporating Radiation Oncology into Immunotherapy" co-sponsored by the American Society of Radiation Oncology (ASTRO), the National Cancer Institute (NCI) and the Society for Immunotherapy of Cancer (SITC), that takes place from June 15 to 16, 2017 in Bethesda, Maryland, USA. more info >> |
|
| Tuesday, June 6, 2017 |
|
|
NANOBIOTIX: Promising Data from Phase I/II Head and Neck Cancer Trial with NBTXR3 Presented at the American Society of Clinical Oncology's Annual Meeting |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, presented the results of the Phase I/II head and neck cancer trial with its lead product candidate, NBTXR3, at the American Society of Clinical Oncology (ASCO), Chicago. more info >> |
|
| Thursday, May 18, 2017 |
|
|
Nanobiotix Announces First Positive Human Data Showing That NBTXR3 Could Become a Backbone in Immuno-Oncology |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced its first set of clinical data from its immuno-oncology (IO) program, showing the potential ability of NBTXR3 to transform "cold" tumors into "hot" tumors. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
JDE Peet's 正式啟用 OMP 的 Unison Planning(TM)，大規模提升供應鏈價值
Apr 1, 2026 21:50 HKT/SGT
|
|
|
JDE Peet's 正式启用 OMP 的 Unison Planning(TM) 系统，大规模提升供应链价值
Apr 1, 2026 21:50 HKT/SGT
|
|
|
JDE Peet's Goes Live with OMP's Unison Planning(TM), Accelerating Supply Chain Value at Scale
Apr 1, 2026 21:50 HKT/SGT
|
|
|
Datavault AI Returns a Second Time for Exclusive Investor Forum at Mar-a-Lago
Apr 1, 2026 21:00: JST
|
|
|
GMG Verified by Advanced Carbons Council & Successful ISO9001 Audit
Apr 1, 2026 21:00 HKT/SGT
|
|
|
Datavault AI 再度現身馬阿拉戈，出席專屬投資者論壇
Apr 1, 2026 20:00 HKT/SGT
|
|
|
Datavault AI 再度亮相马阿拉戈，参加独家投资者论坛
Apr 1, 2026 20:00 HKT/SGT
|
|
|
Datavault AI Returns a Second Time for Exclusive Investor Forum at Mar-a-Lago
Apr 1, 2026 20:00 HKT/SGT
|
|
|
Four leading spring tech fairs will take place in April, featuring over 3,700 exhibitors
Apr 1, 2026 19:52: JST
|
|
|
Four leading spring tech fairs will take place in April, featuring over 3,700 exhibitors
Apr 1, 2026 18:52 HKT/SGT
|
|
|
True IDC Pushes "Security Economy", Breaking Ground on Mega Data Center in EEC with 77-Billion-Baht BOI Investment, Cementing Thailand's No. 1 Position
Apr 1, 2026 18:50 HKT/SGT
|
|
|
China Risun (01907.HK) Reports Strong 37.7% Net Profit Surge in 2025 Amid Industry Challenges
Apr 1, 2026 18:07 HKT/SGT
|
|
|
中國旭陽集團（01907.HK）積極面對行業變化 2025年淨利逆勢增長37.7%
Apr 1, 2026 17:50 HKT/SGT
|
|
|
中国旭阳集团（01907.HK）积极面对行业变化 2025年净利逆势增长37.7%
Apr 1, 2026 17:42 HKT/SGT
|
|
|
CTF Life Collaborates with the HKMC to Refer the Policy Reverse Mortgage Programme and the Reverse Mortgage Programme
Apr 1, 2026 16:20 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
